Literature DB >> 18562275

Saccharides cross-reactive with Bacillus anthracis spore glycoprotein as an anthrax vaccine component.

Joanna Kubler-Kielb1, Evgeny Vinogradov, Haijing Hu, Stephen H Leppla, John B Robbins, Rachel Schneerson.   

Abstract

Bacillus anthracis is a spore-forming bacterium that causes anthrax in humans and in other mammals. The glycoprotein BclA (Bacillus collagen-like protein of anthracis) is a major constituent of the exosporium, the outermost surface of B. anthracis spores. The glycosyl part of BclA is an oligosaccharide composed of 2-O-methyl-4-(3-hydroxy-3-methylbutanamido)-4,6-dideoxy-d-glucose, referred to as anthrose, and three rhamnose residues. A structure similar to anthrose, 4-(3-hydroxy-3-methylbutanamido)-4,6-dideoxy-d-glucose is found in the side chain of the capsular polysaccharide (CPS) of Shewanella spp. MR-4. Under certain growth conditions the bacteria produce a variant CPS lacking one methyl group on the hydroxybutyrate, 4-(3-hydroxybutanamido)-4,6-dideoxy-d-glucose. Contrary to anthrose, neither of the Shewanella CPSs is 2-O methylated. Here, we report that both Shewanella CPS variants react with anti-B. anthracis spore sera. We also found that these antisera reacted with flagellae of Pseudomonas syringae, reported to be glycosylated with a similar terminal saccharide, 4-(3-hydroxybutanamido)-4,6-dideoxy-2-O-methyl-d-glucose. Sera produced by immunization with Shewanella or P. syringae cells bound to B. anthracis spores but not to Bacillus cereus spores in a fluorescent microscopy assay. These experiments show that methylation of the anthrose at the O-2 of the sugar ring and at the C-3 of 3-hydroxybutyrate are not essential for induction of cross-reactive antibodies. We report the preparation, characterization, and antibody responses to protein conjugates of the two variants of Shewanella CPS. Both conjugates induced antibodies that bound to both Shewanella CPS variants by ELISA and to B. anthracis spores, as detected by fluorescent microscopy. We propose the use of Shewanella CPS conjugates as a component of an anthrax vaccine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562275      PMCID: PMC2438422          DOI: 10.1073/pnas.0803897105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Anti-carbohydrate antibodies for the detection of anthrax spores.

Authors:  Marco Tamborrini; Daniel B Werz; Joachim Frey; Gerd Pluschke; Peter H Seeberger
Journal:  Angew Chem Int Ed Engl       Date:  2006-10-06       Impact factor: 15.336

2.  The structure of the capsular polysaccharide of Shewanella oneidensis strain MR-4.

Authors:  Evgeny Vinogradov; Ludmila Nossova; Anton Korenevsky; Terry J Beveridge
Journal:  Carbohydr Res       Date:  2005-07-25       Impact factor: 2.104

3.  Anthrax vaccines: Pasteur to the present.

Authors:  A Scorpio; T E Blank; W A Day; D J Chabot
Journal:  Cell Mol Life Sci       Date:  2006-10       Impact factor: 9.261

4.  Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax.

Authors:  S Cohen; I Mendelson; Z Altboum; D Kobiler; E Elhanany; T Bino; M Leitner; I Inbar; H Rosenberg; Y Gozes; R Barak; M Fisher; C Kronman; B Velan; A Shafferman
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

5.  Synthesis and antigenic analysis of the BclA glycoprotein oligosaccharide from the Bacillus anthracis exosporium.

Authors:  Alok S Mehta; Elke Saile; Wei Zhong; Therese Buskas; Russell Carlson; Elmar Kannenberg; Yvonne Reed; Conrad P Quinn; Geert-Jan Boons
Journal:  Chemistry       Date:  2006-12-13       Impact factor: 5.236

6.  Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel.

Authors:  Darrell E Singer; Rachel Schneerson; Christian T Bautista; Mark V Rubertone; John B Robbins; David N Taylor
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

7.  Synthesis of the antigenic tetrasaccharide side chain from the major glycoprotein of Bacillus anthracis exosporium.

Authors:  David Crich; Olga Vinogradova
Journal:  J Org Chem       Date:  2007-07-28       Impact factor: 4.354

8.  Flagellin glycans from two pathovars of Pseudomonas syringae contain rhamnose in D and L configurations in different ratios and modified 4-amino-4,6-dideoxyglucose.

Authors:  Kasumi Takeuchi; Hiroshi Ono; Mitsuru Yoshida; Tadashi Ishii; Etsuko Katoh; Fumiko Taguchi; Ryuji Miki; Katsuyoshi Murata; Hanae Kaku; Yuki Ichinose
Journal:  J Bacteriol       Date:  2007-07-20       Impact factor: 3.490

9.  Anthrose biosynthetic operon of Bacillus anthracis.

Authors:  Shengli Dong; Sylvia A McPherson; Li Tan; Olga N Chesnokova; Charles L Turnbough; David G Pritchard
Journal:  J Bacteriol       Date:  2008-02-01       Impact factor: 3.490

10.  Inactivation of Bacillus anthracis spores in murine primary macrophages.

Authors:  Haijing Hu; Qila Sa; Theresa M Koehler; Arthur I Aronson; Daoguo Zhou
Journal:  Cell Microbiol       Date:  2006-10       Impact factor: 3.715

View more
  9 in total

1.  The structure of the carbohydrate backbone of the LPS from Shewanella spp. MR-4.

Authors:  Evgeny Vinogradov; Joanna Kubler-Kielb; Anton Korenevsky
Journal:  Carbohydr Res       Date:  2008-06-14       Impact factor: 2.104

2.  Characterization of the enzymes encoded by the anthrose biosynthetic operon of Bacillus anthracis.

Authors:  Shengli Dong; Sylvia A McPherson; Yun Wang; Mei Li; Pengfei Wang; Charles L Turnbough; David G Pritchard
Journal:  J Bacteriol       Date:  2010-07-30       Impact factor: 3.490

3.  Glycosylation of BclA Glycoprotein from Bacillus cereus and Bacillus anthracis Exosporium Is Domain-specific.

Authors:  Emmanuel Maes; Frederic Krzewinski; Estelle Garenaux; Yannick Lequette; Bernadette Coddeville; Xavier Trivelli; Annette Ronse; Christine Faille; Yann Guerardel
Journal:  J Biol Chem       Date:  2016-02-26       Impact factor: 5.157

4.  Identification of an African Bacillus anthracis lineage that lacks expression of the spore surface-associated anthrose-containing oligosaccharide.

Authors:  Marco Tamborrini; Mark Bauer; Miriam Bolz; Angaya Maho; Matthias A Oberli; Daniel B Werz; Esther Schelling; Jakob Zinsstag; Peter H Seeberger; Joachim Frey; Gerd Pluschke
Journal:  J Bacteriol       Date:  2011-05-13       Impact factor: 3.490

5.  Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.

Authors:  Michael Wetter; Michael Kowarik; Michael Steffen; Paula Carranza; Giampietro Corradin; Michael Wacker
Journal:  Glycoconj J       Date:  2012-10-06       Impact factor: 2.916

6.  Giant DNA virus mimivirus encodes pathway for biosynthesis of unusual sugar 4-amino-4,6-dideoxy-D-glucose (Viosamine).

Authors:  Francesco Piacente; Margherita Marin; Antonio Molinaro; Cristina De Castro; Virginie Seltzer; Annalisa Salis; Gianluca Damonte; Cinzia Bernardi; Jean-Michel Claverie; Chantal Abergel; Michela Tonetti
Journal:  J Biol Chem       Date:  2011-12-08       Impact factor: 5.157

7.  Antibody responses to a spore carbohydrate antigen as a marker of nonfatal inhalation anthrax in rhesus macaques.

Authors:  Elke Saile; Geert-Jan Boons; Therese Buskas; Russell W Carlson; Elmar L Kannenberg; John R Barr; Anne E Boyer; Maribel Gallegos-Candela; Conrad P Quinn
Journal:  Clin Vaccine Immunol       Date:  2011-03-09

8.  Anthrax spore detection by a luminex assay based on monoclonal antibodies that recognize anthrose-containing oligosaccharides.

Authors:  Marco Tamborrini; Marcelle Holzer; Peter H Seeberger; Nadia Schürch; Gerd Pluschke
Journal:  Clin Vaccine Immunol       Date:  2010-07-21

9.  Convergent evolution of diverse Bacillus anthracis outbreak strains toward altered surface oligosaccharides that modulate anthrax pathogenesis.

Authors:  Michael H Norris; Alexander Kirpich; Andrew P Bluhm; Diansy Zincke; Ted Hadfield; Jose Miguel Ponciano; Jason K Blackburn
Journal:  PLoS Biol       Date:  2020-12-28       Impact factor: 8.029

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.